Santeri Pakola

9PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 20, 2026
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

|Apr 10, 2026
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.

Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari

|Apr 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.

Tatiana V Kudling, Dmitrii Bychkov, James H A Clubb

|Feb 05, 2025
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää

|Jan 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.

Santeri A Pakola, James H A Clubb, Tatiana V Kudling

|Mar 28, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Santeri A Pakola, Katriina J Peltola, James H A Clubb

Pageof 2

Frequent Collaborators

8 joint publications

Akseli Hemminki

6 joint publications

Elise Jirovec

5 joint publications

Tatiana V Kudling

5 joint publications

Lyna Haybout